Laurus Labs Limited Bombay S.E.

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-24 am EDT			5-day change	1st Jan Change
434.4 ^INR	+0.32%		-1.91%	+0.99%

Apr. 18	Laurus Labs Board to Consider Second Interim Dividend for Fiscal Year 2024	MT
Apr. 15	Laurus Labs Incorporates New JV Company with Slovenia-Based Pharmaceutical Company	MT

Laurus Labs Limited Reaffirms Revenue Guidance for the Fiscal Year 2023

July 30, 2021 at 01:30 am EDT

Laurus Labs Limited reaffirmed revenue guidance for the fiscal year 2023. The company stand reaffirmed on the company's aspirational revenue target of INR 1 billion by fiscal year 2023.

Latest news about Laurus Labs Limited

Laurus Labs Board to Consider Second Interim Dividend for Fiscal Year 2024	Apr. 18	MT
Laurus Labs Incorporates New JV Company with Slovenia-Based Pharmaceutical Company	Apr. 15	MT
Laurus Labs, Slovenia's Krka to Form JV; Laurus Shares Fall 6%	Jan. 26	MT
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd	Jan. 25	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR250 From INR290, Keeps at Underperform	Jan. 25	MT
Laurus Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 24	CI
Transcript : Laurus Labs Limited, Q3 2024 Earnings Call, Jan 24, 2024	Jan. 24
INDIA STOCKS-IT drives losses in Indian shares ahead of Fed policy outcome	Dec. 12	RE
Indian shares set to open higher; focus turns to Fed policy	Dec. 12	RE
Laurus Labs Completes Acquisition of Additional Stake in Laurus Bio	Nov. 21	MT
Laurus Labs Limited completed the acquisition of additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders.	Nov. 19	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR260 From INR250, Keeps at Underperform	23-10-23	MT
Laurus Labs Limited Announces Resignation of Chandrakanth Chereddi as Non-Executive Director	23-10-20	CI
Transcript : Laurus Labs Limited, Q2 2024 Earnings Call, Oct 20, 2023	23-10-20
Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023	23-10-20	CI
Laurus Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-20	CI
Laurus Labs Limited agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.	23-09-10	CI
India's Divi's Labs Q1 profit slumps on drug pricing pressures	23-08-14	RE
Laurus Labs' Consolidated Profit Tanks in Fiscal Q1; Shares Climb 4%	23-07-31	MT
Transcript : Laurus Labs Limited, Q1 2024 Earnings Call, Jul 27, 2023	23-07-27
Laurus Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-27	CI
Laurus Labs Pays First Tranche to Acquire Additional Stake in Cell and Gene Therapy Company	23-07-12	MT
CARE Affirms AA Rating on Laurus Labs' Long-term Bank Financing; Outlook Stable	23-06-27	MT
Laurus Labs Ties Up with Indian Institute for Novel Gene Therapy Advancement in India	23-06-19	MT
Laurus Labs Signs Memorandum of Agreement with IIT Kanpur for Novel Gene Therapy Assets	23-06-19	CI

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Laurus Labs Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

434.4 INR

Average target price

370.1 INR

Spread / Average Target

-14.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Laurus Labs Limited Bombay S.E.

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Laurus Labs Limited Reaffirms Revenue Guidance for the Fiscal Year 2023

Latest news about Laurus Labs Limited

Chart Laurus Labs Limited

Company Profile

Income Statement Evolution

Ratings for Laurus Labs Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals